Allworth Financial LP boosted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 90.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 38,082 shares of the company's stock after buying an additional 18,059 shares during the quarter. Allworth Financial LP's holdings in Kenvue were worth $790,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Grove Bank & Trust increased its holdings in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Kenvue during the 4th quarter valued at about $29,000. Ashton Thomas Securities LLC bought a new stake in Kenvue in the 3rd quarter worth approximately $35,000. Fortitude Family Office LLC lifted its position in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after buying an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after buying an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Kenvue Stock Performance
Kenvue stock traded up $0.84 during mid-day trading on Friday, reaching $23.23. 15,232,077 shares of the stock traded hands, compared to its average volume of 13,461,299. The stock has a market capitalization of $44.53 billion, a PE ratio of 43.78, a price-to-earnings-growth ratio of 2.61 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The business's 50-day moving average is $21.29 and its 200-day moving average is $22.14.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.53%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the company. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Piper Sandler raised Kenvue from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday, January 17th. Finally, Canaccord Genuity Group reduced their target price on Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $23.00.
Read Our Latest Stock Analysis on Kenvue
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
